Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02003898 · ClinicalTrials.gov registry record · NA
Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data
A NA study, sponsored by Medtronic MiniMed.
- Completed
- Registry status
- NA
- Development phase
- 372
- Enrollment target
NCT02003898: Completed NA study, sponsored by Medtronic MiniMed.
NCT02003898 is a NA study that has completed, run by Medtronic MiniMed. The registered enrollment target is 372 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02003898, a NA study, has completed, sponsored by Medtronic MiniMed.
- COMPLETED
- Registry status
- NA
- Development phase
- 372 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the Threshold Suspend (TS) feature of the Medtronic MiniMed® 530G insulin pump in patients 16 and older with insulin requiring diabetes.
Primary Outcome
Comparison of A1C measurement from baseline to end of study in the CEP266 study population. The overall mean change in A1C from baseline will be estimated and compared by a non-inferiority test with an A1C margin of 0.4% and a significance level of 0.025 (one-sided) with the CEP 266 study population.
Interventions
- DEVICE Medtronic MiniMed 530G Insulin Pump
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 372 participants |
| Start Date | 2013-11-26 |
| Est. Completion | 2018-02-20 |
| Phase | NA |
What the finished NCT02003898 record still lists
NCT02003898 is an interventional study that assigns participants to a tested intervention. The registered 372 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Medtronic MiniMed 530G Insulin Pump is the first listed.
NCT02003898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02003898 about?
NCT02003898 is a clinical study titled "Post Approval Study of the TS Feature With the 530G Pump System Supplemented With Commercial Patient Data". The purpose of this study is to evaluate the Threshold Suspend (TS) feature of the Medtronic MiniMed® 530G insulin pump in patients 16 and older with insulin requiring diabetes.
What is the current status of trial NCT02003898?
This trial is currently completed. It is a NA study. The enrollment target is 372 participants. The study started on 2013-11-26. Estimated completion is 2018-02-20.
What interventions are being tested in trial NCT02003898?
The interventions under investigation include: Medtronic MiniMed 530G Insulin Pump (DEVICE).
Who is sponsoring clinical trial NCT02003898?
This trial is sponsored by Medtronic MiniMed, which has 29 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02003898's enrollment target sits among peer trials
372 280th of 2000 higher than 1,720 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04801589 · 372 participants · Phase 3
Goal-Directed Sedation in Mechanically Ventilated Infants and Children
- NCT04879329 · 372 participants · Phase 2
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
- NCT05318105 · 372 participants · NA
Ultrafiltration Versus IV Diuretics in Worsening Heart Failure
- NCT06797635 · 372 participants · Phase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI